Shionogi, established in 1878, is dedicated to developing innovative treatments for global health challenges such as antimicrobial resistance and COVID-19. With a history of introducing novel antibiotics and advanced medications for HIV and influenza, the company continues to advance clinical programs in areas like Fragile X syndrome, acute ischemic stroke, metabolic disorders, and oncology. Driven by a commitment to patient impact, Shionogi fosters strategic partnerships with industry leaders to accelerate scientific advancements and deliver first-in-class therapies worldwide.
Reporting to the VP of Marketing, the Brand Lead will be responsible for developing and implementing all elements of the US Brand Strategy for a novel 3CL protease inhibitor for the prevention of SARS-CoV-2 infection (COVID-19). The ideal candidate will be ‘hands on’ and have the ability to create a superior end-to-end customer experience with a mindset for growth and a “play to win” attitude.
Shionogi, established in 1878, is dedicated to developing innovative treatments for global health challenges such as antimicrobial resistance and COVID-19. With a history of introducing novel antibiotics and advanced medications for HIV and influenza, the company continues to advance clinical programs in areas like Fragile X syndrome, acute ischemic stroke, metabolic disorders, and oncology. Driven by a commitment to patient impact, Shionogi fosters strategic partnerships with industry leaders to accelerate scientific advancements and deliver first-in-class therapies worldwide.